1
00:00:00,160 --> 00:00:05,680
We have to face a number of 
challenges in hematology, and 

2
00:00:05,680 --> 00:00:11,200
one important challenge for me 
is equitable access, equitable 

3
00:00:11,200 --> 00:00:16,040
access to diagnostics, to 
treatments, to emerging 

4
00:00:16,040 --> 00:00:21,720
therapies across all regions. 
Another challenge is to create 

5
00:00:21,720 --> 00:00:27,040
inclusiveness, to take care of 
underrepresented countries and 

6
00:00:27,040 --> 00:00:31,240
to integrate them into research 
and clinical networks. 

7
00:00:31,720 --> 00:00:35,640
Another important challenge is 
to remove borders. 

8
00:00:35,640 --> 00:00:40,840
That's why we have our purpose. 
Borderless hematology. 

9
00:00:40,840 --> 00:00:44,920
Remove borders with regard to 
your graphical borders, 

10
00:00:44,920 --> 00:00:48,480
disciplinary borders, 
hierarchical borders, many, many

11
00:00:48,480 --> 00:00:56,000
borders. 
Welcome to EHA Unplugged, the 

12
00:00:56,000 --> 00:00:59,520
official podcast channel of the 
European Hematology Association.

13
00:00:59,600 --> 00:01:01,920
EHAI am your host Isabella 
Rivera. 

14
00:01:02,080 --> 00:01:05,040
Today we have the privilege of 
speaking with Professor 

15
00:01:05,040 --> 00:01:07,880
Constance Donor. 
She's the current EHA president 

16
00:01:07,880 --> 00:01:11,400
and she's the head of the 
section of Mylod malignancies at

17
00:01:11,400 --> 00:01:15,720
the Department of Hematology at 
all University Hospital in 

18
00:01:15,720 --> 00:01:18,120
Germany. 
Professor Donor is renowned for 

19
00:01:18,120 --> 00:01:22,440
her clinical and scientific 
expertise in myeloproliferative 

20
00:01:22,440 --> 00:01:25,840
neoplasms and acute myeloid 
leukemia, AML. 

21
00:01:26,000 --> 00:01:29,680
In this episode, we'll explore 
her career in hematology, her 

22
00:01:29,680 --> 00:01:33,120
involvement with the HA, and her
vision for the future of the 

23
00:01:33,120 --> 00:01:34,800
field. 
Thank you very much for being 

24
00:01:34,800 --> 00:01:38,320
with us today, Professor Donner.
Thank you very much, Isabel, for

25
00:01:38,320 --> 00:01:40,360
the kind invitation. 
I'm happy to give this 

26
00:01:40,360 --> 00:01:43,000
interview. 
Professor Donner, to start, we 

27
00:01:43,000 --> 00:01:45,040
would like to understand your 
journey hematology. 

28
00:01:45,280 --> 00:01:47,200
What attracted you to 
hematology? 

29
00:01:47,200 --> 00:01:52,360
So my journey started a while 
ago and it started when I was at

30
00:01:52,360 --> 00:01:55,560
the late stage of medical 
school, in the last part of 

31
00:01:55,560 --> 00:01:59,440
medical school and I had to do a
practical part in internal 

32
00:01:59,440 --> 00:02:02,960
medicine and internal medicine. 
At this time it was the 

33
00:02:02,960 --> 00:02:07,120
hematology department at the 
University of Heidelberg, and I 

34
00:02:07,120 --> 00:02:11,200
had no idea at this time what 
hematology means because at 

35
00:02:11,200 --> 00:02:15,440
medical school hematology was 
only a very, very small part of 

36
00:02:15,440 --> 00:02:19,360
our education. 
So I started my work there and I

37
00:02:19,360 --> 00:02:23,240
was surprised by the 
heterogeneity of the different 

38
00:02:23,240 --> 00:02:25,760
diseases. 
I've never heard before the 

39
00:02:25,760 --> 00:02:29,120
opportunities we had that this 
time to treat patients. 

40
00:02:29,120 --> 00:02:33,680
And I was fascinated by these 
blood diseases, I must say, 

41
00:02:33,760 --> 00:02:38,280
because it was very practical. 
You need a microscope. 

42
00:02:38,280 --> 00:02:41,720
You look at the blood smear or 
the bone marrow smear, and you 

43
00:02:41,720 --> 00:02:43,800
learned a lot about the 
diseases. 

44
00:02:44,200 --> 00:02:47,880
And I was also fascinated by the
patients because these patients 

45
00:02:47,880 --> 00:02:50,440
are different. 
You stay with them for a very 

46
00:02:50,440 --> 00:02:52,800
long time. 
You are with them during the 

47
00:02:52,800 --> 00:02:57,040
whole treatment period, and you 
have a kind of relationship to 

48
00:02:57,040 --> 00:02:59,160
them. 
And often they have to come back

49
00:02:59,160 --> 00:03:02,760
for the next treatment. 
Yeah, it was a very emotional 

50
00:03:02,760 --> 00:03:07,920
experience for me and I was 
attracted at this time by the 

51
00:03:07,920 --> 00:03:11,800
heterogeneity of the different 
diseases and what we can do for 

52
00:03:11,800 --> 00:03:15,080
the patients. 
Your clinical work and your 

53
00:03:15,080 --> 00:03:19,160
research have focused on acute 
myeloid leukemia and 

54
00:03:19,200 --> 00:03:22,920
myeloproliferative neoplasms. 
Why did you focus on this 

55
00:03:22,920 --> 00:03:26,000
specifically? 
At this time I started to focus 

56
00:03:26,000 --> 00:03:29,680
on acute myeloid leukemia, a 
disease that is really an 

57
00:03:29,680 --> 00:03:33,240
emergency This in in hematology 
because people come to the 

58
00:03:33,400 --> 00:03:36,040
clinic and they are really, 
really sick and you have to 

59
00:03:36,040 --> 00:03:38,480
react immediately. 
You have to make decisions 

60
00:03:38,480 --> 00:03:41,280
immediately. 
And I was also fascinated 

61
00:03:41,280 --> 00:03:44,800
because at this time in our 
department at the University in 

62
00:03:44,840 --> 00:03:48,440
Hospital in Heidelberg, there 
was a group of people, they were

63
00:03:48,440 --> 00:03:51,920
mainly interested in 
understanding the impact of 

64
00:03:51,920 --> 00:03:54,960
genetic alterations in acute 
myeloid leukemia. 

65
00:03:54,960 --> 00:03:58,520
And at this time we had not 
really much knowledge about the 

66
00:03:58,520 --> 00:04:02,840
impact of genetic alterations. 
We just knew that they play an 

67
00:04:02,840 --> 00:04:06,520
important role for the disease, 
for disease biology, but also 

68
00:04:06,520 --> 00:04:09,360
for outcome. 
And I had the chance to join a 

69
00:04:09,360 --> 00:04:13,240
group quite early in the 
Department of Hematology and to 

70
00:04:13,240 --> 00:04:17,040
start some very small research 
projects together with 

71
00:04:17,040 --> 00:04:20,760
collaborators at other 
scientific institutes in 

72
00:04:20,760 --> 00:04:23,480
Heidelberg. 
And I learned new techniques and

73
00:04:23,480 --> 00:04:26,640
I learned to understand much 
better the biology of the 

74
00:04:26,640 --> 00:04:29,560
disease. 
So that was the main reason why 

75
00:04:29,560 --> 00:04:33,240
I decided to focus on acute 
myeloid leukemia. 

76
00:04:33,240 --> 00:04:37,000
And much later, the 
myeloproliferative malignancies,

77
00:04:37,000 --> 00:04:41,440
the neoblasms became also my 
field of interest because these 

78
00:04:41,440 --> 00:04:44,840
are really rare, often diseases 
and nobody took care of these 

79
00:04:44,840 --> 00:04:48,400
patients because they are not 
acute, they have not an acute 

80
00:04:48,680 --> 00:04:52,280
leukemia, they have chronic 
leukemic diseases and acute 

81
00:04:52,280 --> 00:04:55,080
myeloid leukemia. 
And this myeloproliferative 

82
00:04:55,080 --> 00:04:59,520
neoblasms, they have a lot of 
commonalities also with regard 

83
00:04:59,520 --> 00:05:02,920
to biology. 
So it was obvious for me to also

84
00:05:02,920 --> 00:05:07,240
include these MPNS in my focus 
of interest. 

85
00:05:09,360 --> 00:05:11,920
You have combined it in the 
years clinical and scientific 

86
00:05:11,920 --> 00:05:13,920
work. 
So you you see patients, you 

87
00:05:14,120 --> 00:05:16,440
take care of patients, but 
you're also doing research. 

88
00:05:16,440 --> 00:05:17,960
What? 
What do you find more 

89
00:05:17,960 --> 00:05:22,360
satisfying? 
So there is no priority, to be 

90
00:05:22,360 --> 00:05:27,560
honest, because my scientific 
work translated into clinical 

91
00:05:27,560 --> 00:05:29,880
work. 
So it's very translational 

92
00:05:29,880 --> 00:05:31,840
research. 
And I think this is the most 

93
00:05:31,840 --> 00:05:37,280
fascinating thing that you do 
research on the one side to get 

94
00:05:37,280 --> 00:05:41,080
some new insights on the biology
findings that are new and you 

95
00:05:41,080 --> 00:05:45,800
can translate your findings into
the care of patients, into 

96
00:05:46,080 --> 00:05:49,040
treatment of patients. 
And this was always something 

97
00:05:49,040 --> 00:05:53,560
that fascinated me, not to do 
basic research and do not know 

98
00:05:53,560 --> 00:05:56,720
what happens to your findings 
with regard to the patients. 

99
00:05:56,880 --> 00:06:02,000
It was always very satisfying to
translate your findings directly

100
00:06:02,000 --> 00:06:05,120
into patient care. 
Are you involved in education at

101
00:06:05,120 --> 00:06:07,160
the university also? 
Yes. 

102
00:06:07,160 --> 00:06:10,440
So at university we have to do 
clinical management of the 

103
00:06:10,440 --> 00:06:15,520
patients, we have to do research
and we have to do teaching. 

104
00:06:15,520 --> 00:06:19,320
So we are also responsible for 
teaching students from medical 

105
00:06:19,320 --> 00:06:24,480
school, but also PhD students in
the lab or biologists in your 

106
00:06:24,480 --> 00:06:28,080
lab or medical students that are
doing their thesis. 

107
00:06:28,080 --> 00:06:31,720
So you are responsible for 
teaching and education as well 

108
00:06:31,760 --> 00:06:35,720
in in the University Hospital? 
How did you come to EHA? 

109
00:06:36,480 --> 00:06:37,960
How do you become important in 
UK? 

110
00:06:38,920 --> 00:06:42,040
So because I was working from 
the very beginning in 

111
00:06:42,040 --> 00:06:47,600
hematology, it was at this time 
it was the only association that

112
00:06:47,600 --> 00:06:50,600
was representing hematology in 
Europe. 

113
00:06:50,600 --> 00:06:56,000
And it was very clear for us 
that we want to show our 

114
00:06:56,000 --> 00:07:00,080
findings, that we want to 
represent our findings at 

115
00:07:00,080 --> 00:07:04,880
European meetings. 
And the EHA was from the very 

116
00:07:04,880 --> 00:07:09,440
beginning of the European 
meeting for hematology for our 

117
00:07:09,440 --> 00:07:13,360
department, for me. 
And I had the opportunity to go 

118
00:07:13,360 --> 00:07:16,560
to the Congress at a very early 
time point. 

119
00:07:16,560 --> 00:07:19,440
I was allowed to go there to 
present my abstract. 

120
00:07:19,440 --> 00:07:24,640
And I do remember very well, I 
went to the 1st Congress of EHA 

121
00:07:24,640 --> 00:07:28,800
in Brussels, which is a long 
time ago, and it was a 

122
00:07:28,800 --> 00:07:33,080
completely different meeting. 
So I think we had one, we had 

123
00:07:33,080 --> 00:07:36,000
something about 500 participants
there. 

124
00:07:36,360 --> 00:07:41,160
And I must say I still Remember,
Remember quite clearly seeing 

125
00:07:41,160 --> 00:07:45,760
all these very famous people you
just knew from the papers and 

126
00:07:45,760 --> 00:07:48,280
they were touchable. 
So you can talk to them. 

127
00:07:48,520 --> 00:07:50,320
You had your poster 
presentation. 

128
00:07:50,320 --> 00:07:55,000
It was a very nice atmosphere. 
And you you felt to be part of 

129
00:07:55,000 --> 00:07:58,800
the community and to start 
collaborating and networking and

130
00:07:58,800 --> 00:08:02,040
get to know the people who are 
interested in the same area. 

131
00:08:02,040 --> 00:08:06,920
So I still remember quite well 
these first EHA Congress in 

132
00:08:06,920 --> 00:08:09,480
Brussels. 
What were your first 

133
00:08:09,480 --> 00:08:13,320
contributions to EHA? 
So I mean the the first contact 

134
00:08:13,320 --> 00:08:17,000
was this Congress in Brussels to
get to know to the people who 

135
00:08:17,000 --> 00:08:20,160
are working in hematology. 
We started collaborations 

136
00:08:20,600 --> 00:08:24,080
because of the networking, the 
networking opportunity at this 

137
00:08:24,080 --> 00:08:27,720
time. 
And for us it was very important

138
00:08:27,720 --> 00:08:30,520
to submit our findings to this 
Congress. 

139
00:08:30,880 --> 00:08:34,400
So we had the chance to present 
the findings, to give the first 

140
00:08:34,440 --> 00:08:39,320
oral presentations that we have 
been very excited about and then

141
00:08:39,320 --> 00:08:42,640
we crew up over the time we were
invited. 

142
00:08:42,640 --> 00:08:47,480
I was an invited speaker at EHA.
I joined some of the former HOPE

143
00:08:47,480 --> 00:08:52,120
meetings representing the 
results from EHA Congress. 

144
00:08:52,120 --> 00:08:56,400
And over the time the network 
was growing and my engagement 

145
00:08:56,400 --> 00:09:01,160
was growing over the time with 
with this really great network 

146
00:09:01,160 --> 00:09:05,800
and the collaboration. 
And I was invited by EHA, for 

147
00:09:05,800 --> 00:09:09,560
example, to be part of the 
reviewing process for the 

148
00:09:09,560 --> 00:09:12,880
Congress. 
And we have to work really hard 

149
00:09:12,880 --> 00:09:16,160
and had several meetings to 
review all the abstracts for the

150
00:09:16,160 --> 00:09:19,160
Congress, select invited 
speakers. 

151
00:09:19,160 --> 00:09:22,680
So this was a group of people 
growing together, getting to 

152
00:09:22,680 --> 00:09:27,120
know each other much better. 
And at a certain time point, I 

153
00:09:27,280 --> 00:09:34,000
was also interested to do more 
for EHA and there was the idea 

154
00:09:34,000 --> 00:09:38,920
to try to become a member of the
board of the EHA board. 

155
00:09:38,920 --> 00:09:44,480
And this was in an in 2018. 
And you know, the process, which

156
00:09:44,480 --> 00:09:49,240
is a very competitive process. 
But at this time, I I won the 

157
00:09:49,240 --> 00:09:54,560
ballot and I was very, very 
happy to be in the inner circle 

158
00:09:54,560 --> 00:09:59,840
of EHA, to become a board member
and to do much more than I did 

159
00:09:59,840 --> 00:10:03,480
before and to get involved in 
many, many in the activities of 

160
00:10:03,480 --> 00:10:07,240
EHA. 
You have been involved a lot in 

161
00:10:07,240 --> 00:10:10,360
education in EHA also. 
Was that before being a member 

162
00:10:10,360 --> 00:10:13,840
of sport? 
So when I became a board member,

163
00:10:13,840 --> 00:10:18,520
I was from the beginning of 
interested in outreach programs,

164
00:10:18,520 --> 00:10:22,480
but also in education. 
And at a certain time point, I 

165
00:10:22,480 --> 00:10:25,160
had the chance to become the 
chair of the education 

166
00:10:25,160 --> 00:10:29,280
committee, which I really liked 
very, very much for several 

167
00:10:29,280 --> 00:10:32,240
reasons. 
Because education is one major 

168
00:10:32,240 --> 00:10:35,640
pillar, one major activity of 
EHA. 

169
00:10:35,640 --> 00:10:42,680
And I love to create courses for
diseases that very important for

170
00:10:42,680 --> 00:10:47,520
hematologists to update the 
courses, to provide updated 

171
00:10:47,520 --> 00:10:51,840
information in the field of 
hematology, but also to provide 

172
00:10:51,840 --> 00:10:54,800
mentorship in our mentorship 
programs. 

173
00:10:54,800 --> 00:10:59,480
And I also liked the concept and
the strategy with regard to 

174
00:10:59,480 --> 00:11:03,000
career development, which is 
also part of education. 

175
00:11:03,320 --> 00:11:07,680
So many, many different aspects.
And I really like the many, many

176
00:11:07,680 --> 00:11:12,960
programs that we initiated and 
that we continued within the 

177
00:11:12,960 --> 00:11:15,880
education committee. 
And one highlight was for sure 

178
00:11:15,880 --> 00:11:19,280
the creation of the Lighting the
Flame program. 

179
00:11:19,280 --> 00:11:23,000
This is a career development 
program for really young, very 

180
00:11:23,000 --> 00:11:27,120
young medical students or 
physicians that are just started

181
00:11:27,200 --> 00:11:31,440
in medicine. 
And it was satisfying to get the

182
00:11:31,440 --> 00:11:36,080
feedback and to see that 
education or with this education

183
00:11:36,080 --> 00:11:39,560
programs you can really move 
things forward and you may be 

184
00:11:39,560 --> 00:11:44,080
contribute to standardized care 
of hematologic patients. 

185
00:11:44,600 --> 00:11:48,160
You have come a very long way in
your involvement with the HA. 

186
00:11:48,160 --> 00:11:51,240
Now you're the president. 
As president of Eviche, what do 

187
00:11:51,240 --> 00:11:54,760
you see as the most significant 
challenges and opportunities in 

188
00:11:54,760 --> 00:11:59,000
hematology today? 
We have to face a number of 

189
00:11:59,000 --> 00:12:04,440
challenges in hematology, and 
one important challenge for me 

190
00:12:04,440 --> 00:12:10,040
is equitable access, equitable 
access to diagnostics, to 

191
00:12:10,040 --> 00:12:15,240
treatments, to emerging 
therapies across all regions. 

192
00:12:15,600 --> 00:12:20,800
So this is one major challenge. 
Another challenge is to create 

193
00:12:20,800 --> 00:12:26,080
inclusiveness, to take care of 
underrepresented countries and 

194
00:12:26,080 --> 00:12:30,240
to integrate them into research 
in clinical networks. 

195
00:12:30,600 --> 00:12:32,760
I think this is really very 
important. 

196
00:12:33,400 --> 00:12:37,200
Another important challenge is 
to remove borders. 

197
00:12:37,200 --> 00:12:42,920
That's why we have our purpose, 
borderless hematology, Remove 

198
00:12:42,920 --> 00:12:47,320
borders with regard to your 
graphical borders, disciplinary 

199
00:12:47,320 --> 00:12:50,720
borders, hierarchical borders, 
many, many borders. 

200
00:12:50,960 --> 00:12:54,240
I think this is another 
challenge we we are working on. 

201
00:12:54,240 --> 00:13:00,160
They are more challenges, like 
supporting countries with fewer 

202
00:13:00,160 --> 00:13:05,800
resources through our education 
programs and through training. 

203
00:13:06,240 --> 00:13:09,200
What is the most unexpected 
lesson that you have learned in 

204
00:13:09,200 --> 00:13:12,840
this period? 
It's not a very long time to be 

205
00:13:12,840 --> 00:13:17,040
honest, but I was very proud to 
see what we have achieved over 

206
00:13:17,040 --> 00:13:22,920
the last years. 
I was very proud to see how EHA 

207
00:13:22,920 --> 00:13:27,320
was and is still growing all the
many activities, but I was also 

208
00:13:27,320 --> 00:13:30,800
surprised to see that there are 
that there is a broad 

209
00:13:30,800 --> 00:13:35,760
heterogeneity across Europe and 
beyond with regard to a standard

210
00:13:35,760 --> 00:13:40,360
of care, with regard to medical 
needs, with regard to policy and

211
00:13:40,360 --> 00:13:44,040
regulatory issues. 
So I think there's a lot of 

212
00:13:44,080 --> 00:13:47,520
things that we can still do and 
that we have to work on. 

213
00:13:48,000 --> 00:13:50,920
And this is fascinating on the 
one side. 

214
00:13:51,080 --> 00:13:55,240
But on the other side, as I 
said, I think EHA has developed 

215
00:13:55,480 --> 00:13:59,640
over this long period. 
I'm with EHA significantly and 

216
00:13:59,640 --> 00:14:04,680
we can be very proud of that. 
So what is your vision for EHA 

217
00:14:04,720 --> 00:14:08,600
in the next few years for the 
development of EHA and 

218
00:14:08,640 --> 00:14:12,480
hematology as a field? 
I would like to see that the 

219
00:14:12,480 --> 00:14:16,760
Community is further growing 
that we are speaking with one 

220
00:14:16,760 --> 00:14:21,360
voice across Europe and beyond 
that we fill the the needs and 

221
00:14:21,360 --> 00:14:26,000
the gaps of countries that are 
not having the same standard 

222
00:14:26,400 --> 00:14:30,680
then other countries support 
them, spread knowledge, nurture 

223
00:14:30,680 --> 00:14:34,800
knowledge and support career 
development across all the 

224
00:14:34,800 --> 00:14:39,200
different carrier stages that we
see in hematology. 

225
00:14:39,640 --> 00:14:44,080
And there are many more aspects 
I think I I would like to see 

226
00:14:44,080 --> 00:14:47,400
over the next years. 
And these are aligned with our 

227
00:14:47,400 --> 00:14:51,520
agenda 20-30 with our strategy 
very nicely. 

228
00:14:51,800 --> 00:14:55,840
So I think this is something I 
would like to see a growing 

229
00:14:55,840 --> 00:15:02,120
community as we working on that 
very hard and to address these 

230
00:15:02,240 --> 00:15:05,920
equitable access issues in 
Europe and beyond. 

231
00:15:07,200 --> 00:15:10,400
So there's a lot to do. 
There's a lot to do, but I think

232
00:15:10,440 --> 00:15:13,880
with all the activities that we 
have initiated over the last two

233
00:15:13,880 --> 00:15:18,520
to three years, we are so much 
aligned with our mission and 

234
00:15:18,520 --> 00:15:22,840
vision, with our agenda for the 
next 5 to 6-7 years. 

235
00:15:22,840 --> 00:15:26,280
And we have a plan and it's 
always good to have a plan and 

236
00:15:26,280 --> 00:15:29,800
to work on the plan. 
And we have a wonderful network.

237
00:15:29,800 --> 00:15:33,200
We have wonderful relationships 
with our national society 

238
00:15:33,200 --> 00:15:38,120
partners, so I'm I'm really 
looking forward to move on this 

239
00:15:38,120 --> 00:15:40,680
way. 
So if you want the audience to 

240
00:15:40,680 --> 00:15:44,080
remember one thing of this 
podcast, would it be? 

241
00:15:44,320 --> 00:15:47,440
So hematology is a fascinating 
field. 

242
00:15:47,640 --> 00:15:52,120
It's a great community. 
I grew up in this community. 

243
00:15:52,120 --> 00:15:55,200
I benefit a lot in this 
community. 

244
00:15:56,120 --> 00:16:01,360
EHA is a wonderful association, 
a wonderful organization to 

245
00:16:01,360 --> 00:16:05,360
support hematologists at all 
stages of their career. 

246
00:16:05,880 --> 00:16:10,120
It's a discipline that allows 
you to get connected, to 

247
00:16:10,120 --> 00:16:12,640
collaborate with many other 
disciplines. 

248
00:16:12,640 --> 00:16:15,520
And it's a rapidly evolving 
field. 

249
00:16:15,520 --> 00:16:19,200
Hematology and I have the 
feeling that we achieved a lot 

250
00:16:19,200 --> 00:16:24,440
over the last 20-30 years with 
regard to the treatment of our 

251
00:16:24,440 --> 00:16:28,080
patients. 
And this is our aim to improve 

252
00:16:28,120 --> 00:16:32,600
outcome of our patients. 
And I have a last message, could

253
00:16:32,600 --> 00:16:36,520
only recommend join EHA, join 
the community. 

254
00:16:36,840 --> 00:16:41,760
Everyone will find an area where
he she can contribute. 

255
00:16:41,800 --> 00:16:46,520
It's a great community with lots
of very important activities. 

256
00:16:46,800 --> 00:16:50,640
Thank you very much, Professor 
Donner for this fascinating 

257
00:16:50,640 --> 00:16:53,200
interview and thank you to the 
audience for listening. 

258
00:16:53,200 --> 00:16:57,040
If you enjoyed this episode, 
please like it and please stay 

259
00:16:57,040 --> 00:16:59,280
tuned for more episodes of 
Eagium Plot. 

260
00:16:59,280 --> 00:17:00,640
Thank you very much, Isabel.